Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol oral solution in patients with Rett syndrome
2018-003370-27Phase 2Unknown
- Sponsor
- GW Pharmaceuticals
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Rett syndrome (RTT) comparing Cannabidiol oral solution 15 mg/kg/day with Placebo (2 arms). Status: unknown.
02
Drugs
cannabidiol
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on 2018-003370-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003370-27.